Skip to main content
NewslettersWatchlist

Canadabis Capital Inc(CANB-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.095
Day High0.095
Open:0.095
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Canadabis Capital Inc down on Tuesday (CANB)
AI-generated - The Globe and Mail
CanadaBis Cap: Bottom 25 Performing Stocks Year-to-Date on TSX-V (CANB)
Newswire.ca
Canadabis Capital Expands into European Market with EU-GMP Partners
Newswire.ca
Canadabis Capital Unveils New 60%+ Double-Infused Pre-Roll under Dab Bods Brand, Setting New Standard for THC Potency in Canadian Market
AI-generated - The Globe and Mail
CanadaBis Cap: Top 10 Undervalued Drug Manufacturers Industry Stocks (CANB)
AI-generated - The Globe and Mail
CanadaBis Cap: Bottom 25 Performing Stocks Year-to-Date on TSX-V (CANB)
Newswire.ca
CANADABIS CAPITAL CONFIRMS NO MATERIAL CHANGE
Newswire.ca
CANADABIS CAPITAL, WITH SUB STIGMA GROW, ANNOUNCES FISCAL Q2 2024 RESULTS HIGHLIGHTED BY CONTINUED POSITIVE ADJUSTED EBITDA(1) AND NET INCOME
Newswire.ca
CANADABIS CAPITAL, WITH SUB STIGMA GROW, ANNOUNCES FISCAL Q1 2024 RESULTS HIGHLIGHTED BY YEAR-OVER-YEAR GROWTH IN REVENUE, ADJUSTED EBITDA¹ AND NET INCOME
AI-generated - The Globe and Mail
CanadaBis Cap: Top 25 Performing Stocks Year-to-Date on TSX Venture Exchange (CANB)
Newswire.ca
CANADABIS CAPITAL, WITH SUB STIGMA GROW, CONFIRMS ANOTHER RECORD FISCAL YEAR OF RESULTS IN 2023, HIGHLIGHTED BY SIGNIFICANT GROWTH IN NET REVENUE, GROSS PROFIT AND EARNINGS
AI-generated - The Globe and Mail
CanadaBis Cap: Top 25 Performing Stocks Year-to-Date on TSX Venture Exchange (CANB)
Newswire.ca
CANADABIS CAPITAL, WITH SUB STIGMA GROW, ANNOUNCES INDUSTRY-LEADING ACHIEVEMENT AFTER WINNING PRODUCT OF THE YEAR AWARD AND PROVIDES CORPORATE UPDATE
Newswire.ca
CANADABIS CAPITAL ANNOUNCES RESULTS OF SHAREHOLDERS MEETING AND THE APPOINTMENT OF GARFIELD RICHARDS AS CFO
AI-generated - The Globe and Mail
CanadaBis Cap: Top 25 Performing Stocks Year-to-Date on TSX Venture Exchange (CANB)
Newswire.ca
CANADABIS CAPITAL, WITH SUB STIGMA GROW, ANNOUNCES CONTINUED POSITIVE GROWTH IN FISCAL Q3 2023, HIGHLIGHTED BY 874% INCREASE IN NET INCOME AND POSITIVE EARNINGS PER SHARE
Newswire.ca
CANADABIS CAPITAL, WITH SUB STIGMA GROW, ANNOUNCES ANOTHER RECORD FISCAL PERIOD AS Q2 2023 NET INCOME INCREASED 373% YEAR-OVER-YEAR
ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with CanadaBis Capital, Callinex Mines and Datametrex AI Discussing Their Latest News
Newswire.ca
CanadaBis Capital with Sub Stigma Grow Provides Corporate Update, Highlighted by Ongoing Product Expansion, Significant Growth in Net Revenue and Profitability
Newswire.ca
CANADABIS CAPITAL WITH SUB STIGMA GROW ANNOUNCES RECORD $7.8M REVENUE FOR FISCAL Q1 2023 UP 22% OVER Q4 2022, HIGHLIGHTED BY SIGNIFICANT GROWTH IN NET REVENUE, GROSS PROFIT AND EARNINGS
Newswire.ca
/R E P E A T -- CANADABIS CAPITAL WITH SUB. STIGMA GROW ANNOUNCES RECORD Q4 AND FISCAL YEAR 2022 RESULTS HIGHLIGHTED BY SIGNIFICANT GROWTH IN NET REVENUE, GROSS PROFIT AND EARNINGS/
Newswire.ca
CANADABIS CAPITAL WITH SUB. STIGMA GROW ANNOUNCES RECORD Q4 AND FISCAL YEAR 2022 RESULTS HIGHLIGHTED BY SIGNIFICANT GROWTH IN NET REVENUE, GROSS PROFIT AND EARNINGS
The Globe and Mail
CanadaBis Capital: Top 10 Undervalued Drug Manufacturers Industry Stocks (CANB)
The Globe and Mail
CanadaBis Capital: Top 10 Undervalued Drug Manufacturers Industry Stocks (CANB)
The Globe and Mail
CanadaBis Capital: Top 10 Undervalued Drug Manufacturers Industry Sector Stocks on TSX Venture Exchange (CANB)
Newswire.ca
CANADABIS CAPITAL ANNOUNCES FISCAL Q3 2022 RESULTS HIGHLIGHTED BY RECORD GROSS REVENUE AND CONTINUED PROFITABILITY QUARTER-OVER-QUARTER
AccessWire
Early Warning Report - Shares of CanadaBis Capital Corp
AccessWire
Early Warning Report – Shares of Canadabis Capital Corp.
AccessWire
CanadaBis Capital Corp. Closes Financing
AccessWire
CanadaBis Capital Corp. Announces $550,000 Financing and Purchase by Strategic Investor
AccessWire
CanadaBis Capital Grant Options

Profile

CanadaBis Capital Inc is a vertically-integrated cannabis company. The firm engages in the production and sale of recreational cannabis. Its product line consists of Stigma Roots. It operates in three segments: wholesale, retail, and extraction and tolling. The wholesale segment cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards. Retail segment involves sale of cannabis and cannabis-related products to end consumers on-premise owned and operated by the Company. Extraction and tolling segment provides cannabinoid extraction services to other licensed producers. The company generates maximum of its revenue from Extraction and tolling.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.